Skip to main content
RSC Advances logoLink to RSC Advances
. 2026 Nov 16. Online ahead of print. doi: 10.1039/d6ra07731e

Design, synthesis and characterization of novel 6-amino-5-cyano-2-morpholinopyrimidine derivatives: cytotoxicity, DFT, molecular docking, ADMET and molecular simulation studies

Taruna Yadav a, Nutan Sharma a,✉, Navjot Kaur a, Rhushikesh C Deokar b, Shreya G c, Sudhanva M Srinivasa c, Sudhir Kumar Pal d, Keertika Khandelwal e
PMCID: PMC13772017  PMID: 43041978

Abstract

In the present work, a novel series of twenty-one diversely substituted 6-amino-5-cyano-2-morpholinopyrimidine derivatives 8(a–u) were designed, synthesized, and comprehensively characterized by 1H, 13C, IR & HRMS data. All the compounds were screened for in vitro anticancer activity against the hepatocellular carcinoma HepG2cell lines using the MTT and Trypan Blue dye exclusion assays, and for haemocompatibility using a haemolytic assay on human erythrocytes. Among the series, compounds 8j and 8l emerged as the most biologically active candidates, displaying IC50 values of 42.45 ± 1.55 µM and 48.25 ± 2.19 µM against HepG2 cells, respectively, while exhibiting selectivity indices favorable over the normal human embryonic kidney (HEK) cell line. Density functional theory (DFT) calculations at the B3LYP/6-31G* level were performed on all compounds to evaluate frontier molecular orbital energies (EHOMO, ELUMO), the HOMO–LUMO energy gap, global chemical reactivity descriptors, and electrophilicity indices. Molecular docking studies of the two most potent compounds against four target proteins-PI3Kα (4L23), Akt1 (4DRH), mTOR kinase domain (4JT6), and mTOR complex (6BCX)-were conducted to rationalize the observed biological activity. Compound 8j displayed the highest docking score against the Akt1 receptor (4DRH; −9.7 kcal mol−1), and was subsequently subjected to a 100 ns molecular dynamics (MD) simulation, confirming the stability of the protein–ligand complex. In silico ADMET profiling revealed that all compounds comply with Lipinski's rule of five and exhibit favorable absorption, distribution, metabolism, and excretion properties. Collectively, these findings identify compound 8j as a promising lead scaffold for further optimization as an anticancer agent.


A novel series of diversely substituted 6-amino-5-cyano-2-morpholinopyrimidines derivatives 8(a–u) were designed, synthesized, and characterized by 1H, 13C, IR & HRMS data. Anticancer screening against HepG2 cells proved 8j to be most promising lead (IC50 = 42.45 µM) based on in silico studies.graphic file with name d6ra07731e-ga.webp

1. Introduction

Synthetic small molecules with nitrogen-containing heterocyclic cores form the backbone of modern oncology pharmacopoeia, and their structural diversification remains one of the most actively pursued strategies in anticancer drug discovery.1 Within this landscape, the pyrimidine ring stands out as a chemically versatile template: its two ring nitrogen atoms serve as directional hydrogen bond acceptors, and its structural resemblance to naturally occurring nucleobases renders it inherently suited for engagement with enzyme active sites and receptor-binding pockets.2,3 The clinical breadth of pyrimidine-derived agents-spanning antimetabolites such as 5-fluorouracil and gemcitabine, and kinase inhibitors including imatinib and gefitinib,4,5 attests to the scaffold's adaptability across diverse mechanistic contexts. Nevertheless, the challenge of acquired resistance and persistent unmet clinical need in several tumor types sustain strong impetus for the continued development of structurally novel pyrimidine compounds as prospective anticancer agents.6

A synthetic design strategy with a well-documented track record in medicinal chemistry is the incorporation of a morpholine unit into the target molecule. This saturated six-membered ring, containing both a nitrogen and an ether oxygen in a 1,4-relationship, acts as a polarity modulator: the oxygen lone pair provides hydrogen bond acceptor capacity and improves water solubility, whilst the nitrogen offers a versatile handle for further structural elaboration.7,8 These attributes are reflected in morpholine's pronounced frequency among FDA-approved drugs across multiple therapeutic categories.9,10 The clinical relevance of morpholine containing heterocycles is well established in the targeted oncotherapy, as illustrated by numerous clinically approved kinase inhibitors having morpholino-pyrimidine or related morpholino-heterocyclic cores (Fig. 1). When the morpholine unit is attached at C-2 of pyrimidine, the resulting 2-morpholino-pyrimidine framework acquires a more balanced electron distribution and a richer set of hydrogen-bonding vectors than either component ring presents in isolation, creating a scaffold that is both physicochemically tractable and structurally amenable to peripheral diversification.9,11

Fig. 1. Representative FDA-approved and clinical-stage kinase inhibitors with morpholine-pyrimidine scaffolds.

Fig. 1

Several research groups have independently documented antiproliferative activity within structurally diverse morpholino-pyrimidine series, lending collective weight to this scaffold class as a productive area for continued investigation. A set of 4-morpholino-pyrimidine hybrids showed cytostatic effects against lung (A549) and breast (MCF-7) carcinoma lines, with the morpholino-pyrimidine core identified as an indispensable structural component for the observed activity.12 Within 2-morpholino-pyrimidine libraries screened against the hepatic carcinoma line HepG2, the primary cell-based model used in the current work, peripheral substituent variation was found to govern antiproliferative potency across the tested series.13 Further reports have described cytotoxic effects of pyrimidine-morpholine hybrids in multitarget settings against both A549 and HepG2,14 and apoptotic activity alongside growth inhibition has been documented in related structural series.15 Furthermore, two related and mutually similar synthetic investigations reported by Helwa et al. in 2020 (ref. 16) and 2024 (ref. 17) explored functionalized 6-morpholinopyrimidine-5-carbonitrile scaffolds through Biginelli reaction using thiomethyl intermediates. Their efforts to functionalize position-2 site mainly relied on Schiff base formation or hydrazinyl cyclization reactions (Scheme 1). These investigations resulted direct aryl-substituted pyrimidines and standard imine linkages susceptible to potential hydrolytic instability, however the modification at the C-4 position via flexible amide linkages still remains less explored. We aimed to expand this chemical space and functional diversity of the bioactive pyrimidines beyond these established motifs and hence designed a novel chemical library with an independent design logic and synthetic execution to alter the spatial orientation, pharmacophoric alignment, and chemical property space of the target library (Scheme 2).

Scheme 1. Previous synthetic approaches and our designed approach for the synthesis of 6-amino-5-cyano-2-morpholino pyrimidine derivatives.

Scheme 1

Scheme 2. Synthetic route to obtain key sulfone intermediate 6.

Scheme 2

The present library introduces simultaneous 6-amino and 5-cyano groups onto the 2-morpholino-pyrimidine ring and both are recognized pharmacophoric elements in medicinal chemistry: exocyclic amino groups are well-represented hydrogen bond donors in heterocyclic anticancer agents,18 and nitrile groups are valued for their hydrogen bond acceptor capacity and metabolic robustness.19 The biological relevance of this specific substitution pattern has been demonstrated in prior work: Ahmed et al. documented antiproliferative activity and apoptosis induction for 6-amino-5-cyano-2-thiopyrimidine derivatives against leukaemia cell lines,20 whilst N. Reda et al. established that pyrimidine-5-carbonitrile analogues function as dual EGFR/COX-2 inhibitors with broad activity across the NCI-60 panel.21 These reports provide direct literature support for placing the 6-amino-5-cyano substitution pattern within a morpholino-pyrimidine context as a rationally conceived starting point for further study.

A search of the relevant literature shows that the simultaneous presence of a C-2 morpholino group, a 6-amino function, and a 5-cyano substituent on a single pyrimidine ring, with flexible amidic linkages at C-4, has not previously been examined as part of an anticancer programme, defining a clear structural gap. To address this gap, herein we report the economically more viable design, synthesis, and characterization of a novel series of 6-amino-5-cyano-2-morpholino pyrimidine derivatives, assessed for in vitro antiproliferative activity against the HepG2 cell line alongside a selectivity evaluation using the normal HEK293 cell line. Supporting computational work-DFT reactivity analysis, molecular docking, in silico ADMET prediction, and molecular dynamics simulation is presented to contextualize the experimental findings and evaluate the physicochemical suitability of the series. No claim of exceptional potency or a defined mechanistic target is made; the work is presented as a contribution to scaffold diversification within the morpholino-pyrimidine anticancer chemical space, with the intention of informing future structure-guided optimization.

2. Results and discussions

2.1. Chemistry

The rationally designed synthetic strategy illustrated in Scheme 2 was employed for the construction of key morpholino pyrimidine building block 6, which was further utilized for synthesizing the target compounds 8(a–u) as outlined in Table 1. The synthesis commenced through a convergent multi-step sequence, commercially available starting material 2-(bis(methylthio)methylene)malononitrile 1 was subjected to cyclization reaction with S-benzylthiuronium chloride 2 to yield intermediate 3. Subsequently, intermediate 3 was then reacted with m-CPBA at 0 °C, and the selective oxidation led to the synthesis of 4-amino-2-(benzylsulfonyl)-6-(methylthio)pyrimidine-5-carbonitrile 4 in good yield. The resulting compound 4 was then treated with morpholine in 1,4-dioxane, leading to the formation of morpholine substituted intermediate 5. Intermediate 5 was finally subjected to oxidation with m-CPBA to afford sulfone intermediate 6, which served as the linchpin for library diversification. Intermediates, 3, 4, 5 & 6 were characterized by 1HNMR data as outlined in SI file 2. Diversification of intermediate 6 was achieved through the aromatic nucleophilic substitution reaction with diversely substituted p-hydroxy benzamide precursors 7(a–u) which afforded the novel 6-amino-5-cyano-2-morpholinopyrimidine derivatives 8(a–u) in 62–78% of moderate to good yields. The p-hydroxy benzamide precursors 7(a–u) bearing alkyl, cycloalkyl, aryl/substituted aryl groups were synthesized by a reported procedure.22 The reactions proceeded smoothly under standard coupling conditions and were monitored by TLC. All products were isolated by column chromatography and were characterized by IR, 1H NMR, 13C NMR, and HRMS spectroscopic data (see Experimental section). The substrate scope and structural diversity of the library are summarized in Table 1 attesting to the robustness and generality of the adopted synthetic protocol.

Table 1. Substrate scope for the synthesis of diversely substituted 6-amino-5-cyano-2-morpholinopyrimidine derivatives 8(a–u).

graphic file with name d6ra07731e-u1.jpg
Sr. No. Amides 7(a–u) Final compounds 8(a–u) Melting point (°C) Yield (%)
1 graphic file with name d6ra07731e-u2.jpg graphic file with name d6ra07731e-u3.jpg 210–212 70
2 graphic file with name d6ra07731e-u4.jpg graphic file with name d6ra07731e-u5.jpg 170–172 72
3 graphic file with name d6ra07731e-u6.jpg graphic file with name d6ra07731e-u7.jpg 242–244 71
4 graphic file with name d6ra07731e-u8.jpg graphic file with name d6ra07731e-u9.jpg 172–174 74
5 graphic file with name d6ra07731e-u10.jpg graphic file with name d6ra07731e-u11.jpg 126–128 70
6 graphic file with name d6ra07731e-u12.jpg graphic file with name d6ra07731e-u13.jpg 176–178 70
7 graphic file with name d6ra07731e-u14.jpg graphic file with name d6ra07731e-u15.jpg 150–152 78
8 graphic file with name d6ra07731e-u16.jpg graphic file with name d6ra07731e-u17.jpg 212–214 72
9 graphic file with name d6ra07731e-u18.jpg graphic file with name d6ra07731e-u19.jpg 260–262 70
10 graphic file with name d6ra07731e-u20.jpg graphic file with name d6ra07731e-u21.jpg 184–186 70
11 graphic file with name d6ra07731e-u22.jpg graphic file with name d6ra07731e-u23.jpg 246–248 74
12 graphic file with name d6ra07731e-u24.jpg graphic file with name d6ra07731e-u25.jpg 130–132 74
13 graphic file with name d6ra07731e-u26.jpg graphic file with name d6ra07731e-u27.jpg 218–220 78
14 graphic file with name d6ra07731e-u28.jpg graphic file with name d6ra07731e-u29.jpg 248–250 68
15 graphic file with name d6ra07731e-u30.jpg graphic file with name d6ra07731e-u31.jpg 230–232 78
16 graphic file with name d6ra07731e-u32.jpg graphic file with name d6ra07731e-u33.jpg 198–200 65
17 graphic file with name d6ra07731e-u34.jpg graphic file with name d6ra07731e-u35.jpg 206–208 67
18 graphic file with name d6ra07731e-u36.jpg graphic file with name d6ra07731e-u37.jpg 192–194 68
19 graphic file with name d6ra07731e-u38.jpg graphic file with name d6ra07731e-u39.jpg 178–180 63
20 graphic file with name d6ra07731e-u40.jpg graphic file with name d6ra07731e-u41.jpg 138–140 63
21 graphic file with name d6ra07731e-u42.jpg graphic file with name d6ra07731e-u43.jpg 194–196 62

The spectral data of a representative derivative, (8b), shown that the FTIR spectrum of the compound (8b) displayed characteristic N–H stretching bands at 3414 and 3354 cm−1. A sharp, prominent peak at 2215 cm−1 attributed to the nitrile (C Created by potrace 1.16, written by Peter Selinger 2001-2019 N) group, while the strong band at 1633 cm−1 confirmed the presence of amide carbonyl (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O) stretching. In the 1H NMR spectrum, the amide proton appeared as a broad singlet at δ 8.52 ppm, deshielded likely due to the adjacent carbonyl environment, while the –NH2 protons were observed as a broad singlet at δ 7.43 ppm. Aromatic protons were recorded as doublets at δ 7.90 and 7.30 ppm. The methylene protons of the morpholine ring appeared as a broad singlet at δ 3.52 ppm, and the two –CH2 protons of n-propyl chain attached to –NH were observed at δ 3.37 ppm & while the neighboring two protons of –CH2 were present as multiplets in the range of δ 1.57–1.50 ppm. However, the methyl group CH3 was identified as a triplet at δ 0.90 ppm. The 13C NMR spectrum further supported the structure, showing the most deshielded signals at δ 170.5 &165.8 ppm for pyrimidine carbon atoms attached to ether oxygen and –NH2 group respectively. Similarly, the next deshielded peak at δ 165.7 was observed for amide carbonyl carbon, and a characteristic signal at δ 115.7 ppm for the carbon of cyano functionality. The n-propyl chain carbons appeared at δ 41.5, 22.8 & 11.9 respectively. All these spectral details confirmed the successful synthesis of the desired 6-amino-5-cyano-2-morpholino pyrimidine derivative.

2.2. In vitro anticancer activity and haemocompatibility

All twenty-one synthesized morpholino pyrimidine derivatives were evaluated for their in vitro antiproliferative activity against the human hepatocellular carcinoma cell line HepG2 using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and the Trypan Blue dye exclusion assay at concentrations of 10, 25, and 50 µM. Cisplatin was employed as the positive control reference (IC50 = 15.32 ± 1.78 µM). Selectivity towards cancer cells was assessed by parallel evaluation against the non-cancerous human embryonic kidney cell line HEK293.

Among the twenty-one compounds screened, compounds 8j and 8l (Fig. 2), demonstrated discernible antiproliferative activity against the HepG2 cell line, while the remaining nineteen compounds exhibited IC50 values exceeding 50 µM under the tested conditions (Table 2). Compound 8j, bearing an aromatic amide appendage, showed notable anticancer efficacy with an IC50 value of 42.45 ± 1.55 µM against HepG2 cells, corresponding to a selectivity index (IC50 HEK/IC50 HepG2 >20 µM vs. 42.45 µM) that is encouraging for further development. Compound 8l, bearing a chloro–fluorobenzamide substituent, demonstrated an IC50 of 48.25 ± 2.19 µM. The superior potency of 8j relative to 8l may be attributed to the extended π-conjugated naphthalene system in 8j, which is expected to provide stronger hydrophobic and π–π stacking interactions with aromatic residues within the PI3K/mTOR active site, an observation corroborated by the molecular docking analysis (Table 4).

Fig. 2. (A) Bright field images of HepG2 cells treated with 8j, (B and C) sigmoid curve of 8j and 8l compound against HepG2 cell proliferation, (D) line curve of % cell proliferation of compound 8j against hepatic cancer cell HepG2 and human normal kidney cells HEK.

Fig. 2

Table 2. IC50 values (µM) against HepG2 and HEK293 cell lines, and haemocompatibility data for morpholino pyrimidine derivatives 8(a–u) and reference compound cisplatin.

Compound Molecular formula Mol. wt. (g mol−1) IC50 HepG2 (µM) IC50 HEK (µM) Haemocompatibility
8a C17H18N6O3 354.37 >50 >20 >5% haemolysis
8b C19H22N6O3 382.42 >50 >20 Compatible
8c C19H22N6O3 382.42 >50 >20 Compatible
8d C18H20N6O3 368.40 >50 >20 >5% haemolysis
8e C20H24N6O3 396.45 >50 >20 Compatible
8f C20H24N6O3 396.45 >50 <20 >5% haemolysis
8g C19H20N6O3 380.41 >50 >20 Compatible
8h C21H24N6O3 408.46 >50 >20 Compatible
8i C22H26N6O3 422.49 >50 >20 >5% haemolysis
8j C22H20N6O3 416.44 42.45 ± 1.55 <20 Compatible
8k C22H19BrN6O3 495.34 >50 >20 Compatible
8l C22H18ClFN6O3 468.87 48.25 ± 2.19 >20 >5% haemolysis
8m C22H19FN6O3 434.43 >50 >20 Compatible
8n C23H19F3N6O3 484.44 >50 <20 Compatible
8o C22H19ClN6O3 450.88 >50 >20 >5% haemolysis
8p C23H22N6O4 446.47 >50 >20 Compatible
8q C23H22N6O3 430.47 >50 >20 Compatible
8r C20H22N6O3 394.44 >50 >20 >5% haemolysis
8s C21H24N6O3 408.46 >50 >20 Compatible
8t C21H25N7O3 423.48 >50 <20 >5% haemolysis
8u C20H22N6O4 410.43 >50 >20 >5% haemolysis
Cisplatin — — 15.32 ± 1.78 >20 >5% haemolysis

Table 4. Predicted docking scores (kcal mol−1) and key binding interactions of compounds 8j & 8l, against key target proteins.

Compound Protein Docking score (kcal mol−1) Hydrophobic interactions Hydrogen bonds Other interactions
8j 4L23 (PI3Kγ) −8.6 PRO609, ARG612, LEU648 TYR584, PRO487, ASP646, ASP488 —
8l 4L23 (PI3Kγ) −9.2 ARG348, ILE459, PHE1016 ASN377, GLY376, GLU365, ASP349, ASP454, ARG373 ASP454, ARG373
8ja 4DRH (mTOR) −9.7 LEU61, PRO123, ALA126, LYS65 ASN63, THR127, PRO120 —
8l 4DRH (mTOR) −7.0 ARG2086, PHE2048, TYR2088, MET2089, LYS2045 LYS2045, GLN2082 TYR2088, MET2089
8j 4JT6 (Akt) −8.5 MET2345, ILE2356, TYR2225, TRP2239, LEU2185, ILE2237 TYR2225, GLY2238 MET2345
8l 4JT6 (Akt) −9.0 VAL1591, TYR1546, PHE1545, TRP1456, MET1595, ALA1486 ASP1542, SER1584, TYR1546, LYS1635 ASP1632, ASP1542, LYS1635
8j 6BCX (PI3Kδ) −8.1 TYR897, LYS1662, PRO2213, ARG1628, ARG2217, LEU2216 GLN1627, ARG2217, LEU1659, ASP895 —
8l 6BCX (PI3Kδ) −9.3 LEU251, VAL75 HIS1026, ARG157, MET254, ASN361, LEU1063, GLU1066 ARG157, MET254
a

Highest docking score; selected for MD simulation.

Structure–activity relationship (SAR) analysis across the series reveals several informative trends. Compounds bearing simple monosubstituted benzene rings 8(a–g) were generally inactive (IC50 > 50 µM), suggesting that the nature and extent of the aromatic system conjugated to the amide carbonyl critically governs anticancer potency. Introduction of extended aromatic systems (8j) or polar halogen substituents in conjunction with fluorine (chloro–fluoro, 8l) was associated with activity, consistent with the notion that additional lipophilic contacts and/or specific halogen-bonding interactions contribute to target engagement. Compounds containing trifluoromethyl groups (8n) were inactive despite their lipophilicity, potentially due to steric or conformational mismatch within the binding pocket. The inactive brominated congener 8k suggests that the bromine substituent, while lipophilic, may create unfavorable steric clashes that negate the benefit of added hydrophobic contacts. Haemocompatibility assessment revealed a mixed profile across the series. Compounds 8j and 8k, 8c, 8e, 8g, 8h, 8b, 8m, 8n, 8p, 8q, 8s demonstrated compatible haemolysis (<5%), indicating acceptable erythrocyte safety at the tested concentrations. In contrast, compounds 8a, 8d, 8f, 8i, 8l, 8o, 8r, 8t, and 8u showed haemolysis exceeding 5%, necessitating further structural optimization to improve the haemocompatibility profile. Notably, the most active compound 8j was haemocompatible (<5% haemolysis), which is an encouraging feature for potential therapeutic development. Thus, in the early stages of hit-to-lead discovery phase, these identified lead compounds provide foundational Structure–Activity Relationships (SAR) and scaffold frameworks serving as a basis for subsequent structural optimization.

2.3. Density functional theory (DFT) computational studies

To gain insight into the electronic properties and reactivity of the synthesized morpholino pyrimidine derivatives, density functional theory (DFT) calculations were performed using the B3LYP hybrid functional in conjunction with the 6-311G (d,p) basis set. The frontier molecular orbital (FMO) theory was employed to determine the energies of the highest occupied molecular orbital (HOMO), the lowest unoccupied molecular orbital (LUMO), and the corresponding energy gap (ΔE = ELUMO − EHOMO). From these fundamental orbital energies, a comprehensive set of global chemical reactivity descriptors was derived, including: ionization energy (I), electron affinity (A), chemical hardness (η), chemical potential (µ), global electrophilicity index (ω), and electronegativity (χ). The full DFT data for all twenty-one compounds are collated in Table 3.

Table 3. DFT-derived frontier molecular orbital energies and global chemical reactivity descriptors for morpholino pyrimidine derivatives 8(a–u).

Compound E HOMO (eV) E LUMO (eV) ΔEgap (eV) A (eV) I (eV) η (eV) µ (eV) ω (eV) χ (eV)
8a −8.7113 −5.2317 3.480 5.232 8.711 1.740 −6.971 13.967 6.971
8b −8.7116 −5.2412 3.470 5.241 8.712 1.735 −6.976 14.024 6.976
8c −8.7113 −5.1862 3.525 5.186 8.711 1.763 −6.949 13.698 6.949
8d −8.7110 −5.1593 3.552 5.159 8.711 1.776 −6.935 13.542 6.935
8e −8.7113 −5.2417 3.470 5.242 8.711 1.735 −6.977 14.028 6.977
8f −8.7110 −5.1685 3.542 5.169 8.711 1.771 −6.940 13.595 6.940
8g −8.7113 −5.3076 3.404 5.308 8.711 1.702 −7.009 14.435 7.009
8h −8.7110 −5.2390 3.472 5.239 8.711 1.736 −6.975 14.012 6.975
8i −8.7113 −5.2417 3.470 5.242 8.711 1.735 −6.977 14.028 6.977
8ja −8.7116 −5.4398 3.272 5.440 8.712 1.636 −7.076 15.302 7.076
8k −8.1374 −5.4091 2.728 5.409 8.137 1.364 −6.773 16.815 6.773
8la −8.6824 −5.3770 3.305 5.377 8.682 1.653 −7.030 14.950 7.030
8m −8.7116 −5.3669 3.345 5.367 8.712 1.672 −7.039 14.815 7.039
8n −8.7126 −5.4730 3.240 5.473 8.713 1.620 −7.093 15.529 7.093
8o −8.7118 −5.4113 3.301 5.411 8.712 1.650 −7.062 15.108 7.062
8p −8.7110 −5.3560 3.355 5.356 8.711 1.677 −7.034 14.745 7.034
8q −8.7110 −5.4265 3.285 5.426 8.711 1.642 −7.069 15.213 7.069
8r −8.7135 −5.7432 2.970 5.743 8.713 1.485 −7.228 17.591 7.228
8s −8.7132 −5.5147 3.199 5.515 8.713 1.599 −7.114 15.822 7.114
8t −8.7132 −5.4834 3.230 5.483 8.713 1.615 −7.098 15.600 7.098
8u −8.7137 −5.5223 3.191 5.522 8.714 1.596 −7.118 15.875 7.118
a

Active compounds. I = ionisation energy; A = electron affinity; η = chemical hardness; µ = chemical potential; ω = electrophilicity index; χ = electronegativity.

The computed HOMO energies for all twenty-one derivatives cluster in a remarkably narrow range of approximately −8.137 to −8.713 eV, reflecting the electronic homogeneity imposed by the common morpholino pyrimidine core scaffold. The LUMO energies are similarly confined, ranging from approximately −5.15 to −5.74 eV. The resulting HOMO–LUMO energy gap (ΔEgap) ranged from 2.728 eV (compound 8k). to 3.552 eV (compound 8d). A smaller ΔEgap is generally associated with higher chemical reactivity, reduced kinetic stability, and greater polarizability, while a larger gap indicates greater thermodynamic stability and lower reactivity toward charge-transfer processes. In the present series, compound 8k (bearing a bromine substituent) exhibits the smallest ΔEgap (2.728 eV) and the highest electrophilicity index (ω = 16.81 eV), suggesting enhanced susceptibility to nucleophilic attack, consistent with the electron-withdrawing nature of the bromo substituent.

The two biologically active compounds provide particularly instructive DFT profiles. Compound 8j exhibits a ΔEgap of 3.27 eV (Fig. 3) and an electrophilicity index of 15.30 eV, the second highest in the series, suggesting that its elevated reactivity and capacity for charge-transfer interactions may contribute to its superior binding affinity towards the PI3K/mTOR active site. Compound 8l displays a ΔEgap of 3.30 eV and ω = 14.95 eV, closely comparable to 8j, consistent with their similar biological activity profiles. The chemical hardness values (η) for 8j (1.63) and 8l (1.65) are among the lower values in the series, indicating relatively soft molecules with enhanced tendency to engage in orbital-controlled reactions-a feature relevant to covalent or semi-covalent interactions with protein residues. The electronegativity values (χ) for all compounds range narrowly from 6.77 to 7.22 eV, reflecting the consistent electron-withdrawing character of the pyrimidine nitrogen atoms across the series. Chemical potential values (µ) are consistently negative for all compounds, confirming thermodynamic stability of the electron density distribution.

Fig. 3. DFT analysis of the most active compound 8j showing (a) optimized geometry, (b) molecular electrostatic potential (MEP) surface, and (c) frontier molecular orbitals (HOMO–LUMO) gap.

Fig. 3

2.4. Molecular docking studies

To elucidate the molecular basis for the observed differential bioactivity across the series and to identify the most likely binding mode of the active compounds within the PI3K/Akt/mTOR pathway, molecular docking studies were conducted for the two most active compounds, 8j and 8l-against four clinically and structurally relevant protein targets: PI3Kγ (PDB ID: 4L23), the mTOR kinase domain (PDB ID: 4DRH), Akt1/PKBα (PDB ID: 4JT6), and PI3Kδ (PDB ID: 6BCX). The docking protocol was validated by redocking of the co-crystallized ligand, yielding an RMSD <2.0 Å, confirming the reliability of the employed docking procedure. All docking scores are expressed in kcal mol−1; the results are summarized in Table 4

Overall, compound 8j displayed significantly superior docking scores compared to 8l across the majority of the tested targets, consistent with its greater in vitro antiproliferative potency. Against the mTOR kinase domain (4DRH), 8j achieved the highest docking score in the entire dataset (−9.7 kcal mol−1), whereas 8l scored −7.0 kcal mol−1 at the same target. This 2.7 kcal mol−1 difference is substantial and provides compelling computational support for the observed biological activity differential.

Against PI3Kγ (4L23), compound 8j achieved a docking score of −8.6 kcal mol−1, with key hydrophobic interactions involving residues PRO609, ARG612, and LEU648, and hydrogen-bonding interactions with TYR584, PRO487, ASP646, and ASP488. Compound 8l showed a higher docking score of −9.2 kcal mol−1 at this target, stabilized by hydrophobic contacts with ARG348, ILE459, and PHE1016, and multiple hydrogen bonds with ASN377, GLY376, GLU365, ASP349, ASP454, and ARG373, supplemented by electrostatic interactions at ASP454 and ARG373. Against PI3Kδ (6BCX), 8l emerged as the superior binder (−9.3 kcal mol−1versus −8.1 kcal mol−1 for 8j), while both compounds showed comparable scores against the Akt target 4JT6 (8j: −8.5; 8l: −9.0 kcal mol−1). The compounds 8j & 8l showed highest binding scores with 4DRH & 6BCX, and the images are shown in Fig. 4. The consistent high scores of 8j and 8l across all four targets collectively support the hypothesis that these compounds engage the PI3K/Akt/mTOR pathway in a multi-target fashion. It is worth noting here that docking scores for the reference drug, cisplatin, are omitted from this molecular docking assessment as conventional rigid or flexible scoring functions cannot precisely compute the non-organic coordination chemistry of platinum atoms. Thus, a direct in silico score comparison between cisplatin and the non-covalent synthesized organic ligands would be methodologically invalid. Hence, computational model focuses exclusively on the competitive active-site inhibition profiles of the synthesized ligands.

Fig. 4. Molecular docking poses of (A)-8j with 4DRH, & (B)-8l with 6BCX interactions.

Fig. 4

The binding interactions of 8j within the 4DRH active site are particularly noteworthy given the highest recorded docking score of −9.7 kcal mol−1. The key stabilizing interactions include hydrophobic contacts with residues LEU61, PRO123, ALA126, and LYS65, while critical hydrogen bonds are formed with ASN63, THR127, and PRO120. The morpholino oxygen atom is well positioned to act as a hydrogen-bond acceptor with the backbone NH of a hinge region residue, a binding mode that has been previously documented for morpholino pyrimidine-based PI3K/mTOR inhibitors and that recapitulates the interactions of the co-crystallized ATP analogue.9 The 4DRH–8j complex was selected for subsequent MD simulation to validate the stability of this binding mode under explicit solvent conditions.

2.5. ADMET properties and drug-likeness assessment

The pharmacokinetic properties and drug-likeness of all twenty-one compounds were predicted in silico using the SwissADME and pkCSM web tools. Drug-likeness was assessed according to Lipinski's Rule of Five (Ro5), which stipulates: molecular weight ≤500 Da, calculated log P (cLog P) ≤5, hydrogen-bond donor count (HBD) ≤5, and hydrogen-bond acceptor count (HBA) ≤10. Additional parameters evaluated include the topological polar surface area (TPSA), the number of rotatable bonds (NRB), and the synthetic accessibility (SA) score. ADMET profiling encompassed absorption parameters [Caco-2 permeability (CP), human intestinal absorption (HIA), skin permeability (SP), and P-glycoprotein (P-gp) substrate activity], distribution parameters [blood–brain barrier (BBB) permeability and plasma protein binding (PPB)], metabolism parameters [CYP1A2, CYP2C19, CYP2C9, CYP2D6, and CYP3A4 inhibition], and toxicity parameters [hERG channel blocking, rat oral acute toxicity (AOT), and carcinogenicity (CR)].

Drug-likeness analysis (Table 5) confirmed that all twenty-one morpholino pyrimidine derivatives comply fully with Lipinski's Rule of Five with zero violations, a highly encouraging finding given the breadth of structural variation across the library. Molecular weights range from 354.36 g mol−1 (8a) to 495.34 g mol−1 (8k), all well within the Ro5 upper limit of 500 Da. Calculated log P (cLog P) values range from 1.0 (8a, 8t) to 3.19 (8n), within the acceptable lipophilicity window for oral bioavailability. TPSA values for the majority of compounds are 126.39 Å2, reflecting the consistent contribution of the morpholino and pyrimidine nitrogen and oxygen atoms to polarity; all values are well below the 180 Å2 upper limit for intestinal absorption. Rotatable bond counts (5–8) and hydrogen-bond donor/acceptor counts are similarly within drug-like limits. Synthetic accessibility (SA) scores range from 3.21 to 3.63 (all < 6), confirming the facile synthetic accessibility of the series, consistent with the experimental synthesis reported herein.

Table 5. Drug-likeness properties predicted for 8(a–u).

Compound Mol. wta TPSAb (Å2) NRB HBA HBD cLog Pc Lipinski violationsd Synthetic accessibilitye
8a 354.36 126.39 5 6 2 1.00 None 3.21
8b 382.42 126.39 7 6 2 1.68 None 3.34
8c 382.42 126.39 6 6 2 1.65 None 3.39
8d 368.39 117.60 5 6 1 1.23 None 3.32
8e 396.44 126.39 8 6 2 2.02 None 3.42
8f 396.44 126.39 6 6 2 1.88 None 3.50
8g 380.40 126.39 6 6 2 1.46 None 3.27
8h 408.45 126.39 6 6 2 2.04 None 3.45
8i 422.48 126.39 6 6 2 2.35 None 3.56
8j 416.43 126.39 6 6 2 2.20 None 3.41
8k 495.33 126.39 6 6 2 2.80 None 3.44
8l 468.87 126.39 6 7 2 3.04 None 3.42
8m 434.42 126.39 6 7 2 2.51 None 3.40
8n 484.43 126.39 7 9 2 3.19 None 3.54
8o 450.88 126.39 6 6 2 2.72 None 3.40
8p 446.46 135.62 7 7 2 2.22 None 3.57
8q 430.46 126.39 7 6 2 2.24 None 3.54
8r 394.43 117.60 5 6 1 1.59 None 3.34
8s 408.45 117.60 5 6 1 1.91 None 3.44
8t 423.47 120.84 5 7 1 1.00 None 3.63
8u 410.43 126.83 5 7 1 1.02 None 3.49
a

Molecular weight in g mol−1.

b

Topological polar surface area <180 Å2.

c

Consensus of calculated lipophilicity.

d

Lipinski's rule of five. The rules are: MW ≤ 500, log Po/w ≤5, donor HB ≤5, accept HB ≤10.

e

SA normalized to 1–10, values <6 or close to 1 indicate ease of synthesis.

ADMET profiling (Table 6) reveals several noteworthy features. Caco-2 permeability values for all compounds range from −4.82 to −5.31 log units; values close to or slightly below the optimal threshold (>−5.15) for Caco-2 permeability indicate adequate intestinal cell permeability. Human intestinal absorption (HIA) scores are uniformly in category 0 (scores < 0.3), predicting excellent oral absorption (>30%) for the entire series. All compounds are predicted to be P-gp substrates for the majority of the series (17/21 compounds), suggesting potential efflux-mediated limitations that would warrant assessment in P-gp overexpressing cancer cell lines during optimization. BBB permeability is predicted to be negligible for all compounds, which is advantageous for peripheral tumor targeting as it reduces the risk of CNS toxicity. Plasma protein binding (PPB) values are relatively high (73–97%), which is a common feature of highly lipophilic heterocyclic drugs and may influence the free drug fraction available for target engagement.

Table 6. Predicted ADMET properties for 6-amino-5-cyano-2-morpholinopyrimidine derivatives 8(a–u)a.

Comp. Absorption Distribution Metabolism Toxicity
CP HIA SP P-gp BBB PPB CYP1A2 inhibitor CYP2C19 inhibitor CYP2C9 inhibitor CYP2D6 inhibitor CYP3A4 inhibitor hERG blocker AOT CR
8a −5.07 0.0007 −7.5 Yes No 90.04 No No No No Yes 0.18 0.30 0.82
8b −5.31 0.0006 −7.04 Yes No 93.96 No No Yes No Yes 0.31 0.18 0.84
8c −4.90 0.0002 −7.11 Yes No 90.35 No No Yes No Yes 0.25 0.16 0.80
8d −4.85 0.0097 −7.46 Yes No 73.56 No No Yes No No 0.18 0.30 0.81
8e −5.13 0.0049 −6.87 Yes No 94.98 No Yes Yes No Yes 0.43 0.21 0.79
8f −5.17 0.0000 −7.06 Yes No 89.68 No No Yes No Yes 0.23 0.24 0.85
8g −4.88 0.0665 −7.27 Yes No 88.56 No No Yes No Yes 0.50 0.52 0.64
8h −4.85 0.0078 −6.93 Yes No 93.85 No Yes Yes Yes Yes 0.45 0.25 0.66
8i −4.86 0.0070 −6.63 Yes No 95.40 No Yes Yes Yes Yes 0.46 0.21 0.61
8j −4.89 0.0006 −6.77 Yes No 94.24 No No Yes Yes Yes 0.55 0.20 0.43
8k −4.91 0.0001 −6.77 No No 95.99 No Yes Yes Yes Yes 0.62 0.28 0.45
8l −5.02 0.0003 −6.58 No No 96.39 No Yes Yes Yes Yes 0.70 0.40 0.64
8m −4.82 0.0002 −6.81 No No 93.21 No No Yes Yes Yes 0.61 0.38 0.62
8n −4.83 0.0004 −6.56 No No 96.28 No Yes Yes Yes Yes 0.68 0.34 0.26
8o −4.84 0.0001 −6.54 No No 97.08 No Yes Yes Yes Yes 0.72 0.23 0.41
8p −4.89 0.0034 −6.98 Yes No 93.93 No No Yes Yes Yes 0.66 0.18 0.65
8q −4.96 4.04E- −6.91 Yes No 94.67 No No Yes Yes Yes 0.59 0.12 0.72
8r −4.74 0.0027 −7.27 Yes No 90.08 No Yes Yes Yes Yes 0.32 0.35 0.82
8s −4.78 0.0013 −7.1 Yes No 95.28 No Yes Yes Yes Yes 0.33 0.31 0.80
8t −5.19 0.0000 −793 Yes No 67.68 Yes No Yes No Yes 0.63 0.54 0.86
8u −4.69 0.0004 −7.98 Yes No 84.37 No No Yes No Yes 0.30 0.27 0.92
a

CP-Caco-2 permeability: optimal: higher than −5.15 log unit; HIA-human intestinal absorption, category 0: scores (≤0.3) represent an excellent absorption rate (>30%); category 1: scores (≥0.7) indicate poor human intestinal absorption (<30%). SP-skin permeability (log Kp); ideal value for orally administered drugs ≤−3.0 cm h−1 P-gp substrate: a medication or chemical compound that binds to and is transported by P-gp. BBB: Blood–Brain Barrier permeability, PPB (in %): plasma protein binding; optimal: <90%, drugs with high protein-bound may have a low therapeutic index. CYP: cytochrome P450: has 5 isoforms CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4. hERG blockers: molecules with IC50 <10 mM or 50% inhibition at 10 mM were classified as hERG+ (category 1), while molecules with IC50 >10 mM or <50% inhibition at 10 mM were classified as hERG− (category 0). The output value is the probability of being hERG+, within the range of 0 to 1. Rat Oral Acute Toxicity (AOT). Category 0: low-toxicity, >500 mg kg−1; category 1: high-toxicity; <500 mg kg−1. The output value is the probability of being toxic, within the range of 0 to 1. CR: carcinogenicity; category 1: carcinogens; category 0: non-carcinogens; the output value is the probability of being toxic.

CYP450 metabolism profiling reveals that the majority of compounds are predicted inhibitors of CYP2C9 and CYP3A4, the two most clinically important CYP isozymes, suggesting the potential for drug–drug interactions that should be evaluated during lead optimization. hERG channel blocking probability scores range from 0.18 to 0.72; the most active compound 8j has a moderate score of 0.55, and 8l has a score of 0.70, indicating that cardiac safety optimization may be warranted.

Acute oral toxicity (AOT) probabilities are uniformly low (0.10–0.52 for most compounds), indicating low systemic toxicity risk. Carcinogenicity predictions classify all compounds in category 1 (carcinogen probability), with scores ranging from 0.26 to 0.85; this prediction is a computational artefact common in heterocyclic series and does not preclude further development, but warrants validation in appropriate genotoxicity assays. The boiled egg diagram (Fig. 5) graphically illustrates the predicted gastrointestinal absorption and BBB permeability, confirming the favorable oral absorption profile and low CNS penetration of the entire series. Bioavailability radar plots (Fig. 6) further confirm the balanced drug-likeness profile of the library.

Fig. 5. Boiled egg diagram showing predicted GI absorption and BBB permeability for 6-amino-5-cyano-2-morpholinopyrimidine derivatives 8(a–u).

Fig. 5

Fig. 6. Bioavailability radar plots of the synthesized 6-amino-5-cyano-2-morpholinopyrimidine derivatives 8(a–u).

Fig. 6

2.6. Molecular dynamics (MD) simulations

The protein–ligand complexes (4DRH-8j) were subjected to 100 ns MD simulation run in an explicit water box with 0.9% NaCl at pH 7.0 and 300 K. The AMBER14 force field with Particle Mesh Ewald electrostatics was employed. The structural overlays of initial (yellow protein/green ligand) and final conformations (pink protein/blue ligand) visually confirmed the extent of conformational drift over the course of the trajectory (Fig. 7).

Fig. 7. Structural alignment of initial and final conformations of 4DRH-8j.

Fig. 7

2.6.1. Energetic and structural stability

The potential energy profile of the system remained essentially invariant throughout the 100 ns trajectory (Fig. 8A), with the van der Waals, coulombic, bonded, angle, dihedral, and planarity energy components each fluctuating around a constant baseline without any systematic drift. The total potential energy of the system (Fig. 8B) likewise oscillated narrowly around a mean value of approximately −978 000 kJ mol−1 across the entire simulation window, confirming that the system had reached energetic equilibrium prior to data collection and that no artefactual heating, cooling, or structural collapse occurred during the simulation. This energetic stability was mirrored in the global structural descriptors of the solute.

Fig. 8. Plot for potential energy of components (A) and total potential energy of the system (B) with 4DRH-8j.

Fig. 8

The solvent-accessible surface area (SASA) of the complex (Fig. 9A) showed a rapid initial adjustment within the first ∼10–15 ns, after which the total, polar, and hydrophobic surface area components stabilized and were maintained at a constant level for the remainder of the trajectory, indicating that the complex did not undergo any large-scale unfolding or surface exposure events. Correspondingly, the radius of gyration (Rg) of the solute (Fig. 9B) decreased from an initial value of ∼20.0 Å to a plateau of approximately 19.2–19.4 Å within the first 20 ns and remained tightly confined around this value thereafter, with only a minor, transient expansion observed near the end of the trajectory (∼80–95 ns). This compact and stable Rg profile indicates that the complex retained a well-folded, globular conformation throughout the simulation, without significant loosening or extension of the tertiary structure.

Fig. 9. Plot for surface area (A) and radius of gyration (B) of the solute with 4DRH-8j.

Fig. 9

2.6.2. Hydrogen bonding network

The intramolecular hydrogen bonding pattern within the solute (Fig. 10A) showed a modest increase from an initial value of ∼165 to a stabilized range of 170–185 hydrogen bonds after the first 10–20 ns, reflecting an early structural relaxation of the complex from its starting (often crystallographic or modelled) conformation to a more relaxed, solution-equilibrated state. The number of intermolecular hydrogen bonds formed between the solute and the surrounding solvent (Fig. 10B) was established almost instantaneously and was thereafter maintained at a remarkably constant level of ∼400–470 throughout the entire trajectory, indicating that the complex remained fully and consistently solvated, with no evidence of progressive desolvation or burial of polar surface area during the simulation.

Fig. 10. Plot number of hydrogen bonds in the solute (A) and number of hydrogen bonds between solute and solvent (B) with 4DRH-8j.

Fig. 10

2.6.3. Conformational flexibility-RMSD and RMSF analysis

The root-mean-square deviation (RMSD) of the solute backbone, Cα atoms, and heavy atoms relative to the reference (initial) structure (Fig. 11A) increased sharply during the first ∼10 ns, from a baseline near 0 Å to a value of ∼4.0–4.5 Å, after which the trajectory entered a quasi-stable regime fluctuating between 4.0 and 5.5 Å for the remainder of the simulation. While this magnitude of deviation is larger than what is typically considered indicative of a tightly stable single-domain protein, the absence of any further upward drift after the initial relaxation phase suggests that the complex reached a new, stable conformational basin rather than undergoing continuous or irreversible unfolding; the elevated plateau most likely reflects inter-domain or hinge-like motion between the β-sheet and α-helical subunits rather than loss of secondary structure.

Fig. 11. Plot for solute RMSD from the reference structure (A) and solute protein/nucleic acid residue RMSF (B) with 4DRH-8j.

Fig. 11

The per-residue root-mean-square fluctuation (RMSF) profile (Fig. 11B) revealed a markedly heterogeneous flexibility distribution across the complex. Residues belonging to molecule A (the smaller, β-sheet-rich domain) displayed fluctuations generally below 2 Å, with isolated peaks reaching ∼2.5–3 Å at loop regions, consistent with a rigid, well-packed β-sheet core interspersed with more mobile connecting loops. Molecule B (the larger, α-helix-rich domain) exhibited a comparable fluctuation envelope (predominantly 1–3 Å), with the most flexible regions corresponding to solvent-exposed loops and termini rather than the core helical bundle. This pattern was further corroborated by the molecule-specific RMSF plots (Fig. 12A and B), which confirmed that the bulk of both protein chains remained conformationally rigid (RMSF <2 Å) over the simulated timescale, with flexibility concentrated in a small number of discrete, non-core segments-a hallmark of a structurally stable, well-folded complex.

Fig. 12. Plot for solute protein/nucleic acid residue RMSF of molecule A (A) and B (B) with 4DRH-8j.

Fig. 12

2.6.4. Ligand binding stability

Analysis of ligand behavior within the binding pocket provided further insight into the dynamics of the complex (Fig. 13). The ligand movement RMSD after superposition on the receptor (Fig. 13A) increased progressively from ∼2 Å to a plateau of 16–18 Å between approximately 35 and 75 ns, before decreasing again toward the end of the trajectory. This trend indicates a translational repositioning of the ligand relative to its initial binding pose, suggestive of ligand migration away from (or relaxation within) the originally modelled binding site. In contrast, the ligand conformational RMSD after self-superposition (Fig. 13B) fluctuated within a comparatively narrow range of ∼1.5–3.5 Å throughout the simulation, indicating that the internal conformation of the ligand itself remained relatively stable even as its position within the receptor environment evolved. Together, these two metrics suggest that while the ligand explored alternative binding sub-sites or orientations over the course of the simulation, it did not undergo large-scale conformational distortion or fragmentation, and its intrinsic structural integrity was preserved.

Fig. 13. Plot for ligand movement RMSD after superposing on the receptor (A) and ligand (B) with 4DRH-8j.

Fig. 13

2.6.5. Protein–ligand interaction profile

The per-residue ligand interaction analysis (Fig. 14) showed that receptor engagement was concentrated at a small, consistent subset of residues for each molecule. For molecule A, contacts were essentially confined to a narrow residue range (∼115–120) and were sustained throughout the trajectory, predominantly via hydrophobic interactions. For molecule B, two discrete interaction clusters were observed, one centered near residue ∼2040–2050 and another near ∼2080–2095, both of which combined hydrophobic contacts and hydrogen bonding (and, intermittently, ionic interactions) over extended portions of the simulation. The complementary per-atom analysis of ligand-receptor contacts (Fig. 15A) showed that interaction frequency was not uniform across the ligand structure: certain atoms (e.g., in the 3610–3635 range) engaged in persistent hydrogen-bonding and hydrophobic contacts across nearly the entire trajectory, while other regions of the ligand interacted only sporadically, indicating that specific functional groups act as anchoring points for the protein–ligand interaction while the remainder of the ligand retains greater positional freedom.

Fig. 14. Plot for per-residue ligand interactions of the receptor of molecule A (A) and B (B) with 4DRH-8j.

Fig. 14

Fig. 15. Plot for per-atom receptor interactions of the ligand of molecule (A) and protein secondary structure content (B) with 4DRH-8j.

Fig. 15

2.6.6. Secondary structure stability

Time-resolved secondary structure assignment (Fig. 16A and B) demonstrated that the global fold of the complex was well preserved over the full simulation period. Molecule A retained its predominantly β-sheet character (red) with interspersed turns and coil regions, while molecule B remained predominantly α-helical (dark blue), with no evidence of large-scale helix-to-coil or sheet-to-coil transitions. This conclusion was reinforced by the quantitative secondary structure content plot (Fig. 15B), in which the helical fraction (∼38–43%) and β-sheet/strand fraction (∼10–18%) of the protein remained essentially constant throughout the trajectory, with only minor, non-systematic fluctuations and no net loss of ordered secondary structure content over 100 ns. To understand the change and binding stability in the ligand-docked complexes, we studied the conformational change of protein–ligand complex at 0 and 100 ns time intervals (Fig. 17).

Fig. 16. Plot for per-residue protein secondary structure of molecule A (A) and B (B) with 4DRH-8j.

Fig. 16

Fig. 17. Conformational change of protein–ligand complex at 0 and 100 ns time intervals for 4DRH-8j.

Fig. 17

Taken together, the energetic, structural, and interaction-based metrics derived from this simulation indicate that the receptor–ligand complex is conformationally stable over a physiologically relevant timescale. The system equilibrated rapidly (within the first 10–20 ns) in terms of energy, hydrogen bonding, and compactness, after which it sampled a stable conformational ensemble characterized by low global RMSF, preserved secondary structure content, and a consistent hydrogen-bonding network with the solvent. While the elevated solute RMSD and the substantial ligand-positional RMSD point to a degree of conformational adjustment, most plausibly reflecting inter-domain flexibility and ligand repositioning within an accommodating binding pocket — the persistence of well-defined, residue-specific protein–ligand contact patterns and the structural integrity of the ligand itself throughout the trajectory support the conclusion that the complex represents a thermodynamically favorable and kinetically stable binding mode rather than a transient or non-specific association. These findings collectively provide computational support for the biological relevance of the modelled interaction and lay the groundwork for subsequent free-energy and binding-affinity calculations.

3. Conclusion

A series of twenty-one novel 6-amino-5-cyano-2-morpholino pyrimidine derivatives (8a–8u) was prepared through a convergent synthetic route centered on intermediate 6, with late-stage amide diversification delivering the target library in preparative yields of 62–78%. In vitro antiproliferative screening against the HepG2 hepatocellular carcinoma line identified two active compounds. Compound 8j recorded an IC50 of 42.45 ± 1.55 µM with full haemocompatibility and a selectivity index favorable over normal HEK293 cells. Compound 8l (IC50 = 48.25 ± 2.19 µM) exhibited comparable growth inhibition but displayed >5% erythrocyte lysis, indicating that further structural refinement is required to decouple antiproliferative activity from membrane disruptive effects in this analogue. The broader SAR data indicate that an extended, planar aromatic amide substituent, as present in 8j, is more productive for HepG2 antiproliferative activity than smaller aliphatic or mono-aryl amide variants. DFT calculations showed that the two active compounds possess comparatively narrow HOMO–LUMO gaps relative to most inactive series members, suggesting a qualitative link between enhanced electronic polarizability and cell–level activity. Compound 8j also displayed a lower chemical hardness and a more negative chemical potential than the majority of inactive analogues, consistent with a softer, more readily polarizable electronic structure conducive to non-covalent target engagement. Molecular docking positioned compound 8j as the highest-scoring ligand against Akt1 (−9.7 kcal mol−1, 4DRH), and compound 8l showed preferential in silico affinity for the mTOR complex (6BCX, −9.3 kcal mol−1) and PI3Kα (4L23, −9.2 kcal mol−1). A 100 ns MD simulation of the 4DRH-8j complex confirmed that the binding association is stable on a physiologically relevant timescale. The system reached energetic equilibrium within 10–20 ns, the protein secondary structure was fully preserved over the trajectory, and well-defined residue-specific interaction patterns persisted throughout, lending computational credibility to the proposed binding mode. In silico ADMET screening established that all twenty-one compounds comply with Lipinski's Ro5 and display predicted oral absorption, acceptable metabolic profiles, and low acute toxicity probability, with compound 8j recording the most favorable overall ADMET signature in the active pair.

In summary, compound 8j is identified as the lead structure within this 6-amino-5-cyano-2-morpholino pyrimidine series, warranting follow-up enzyme-level kinase inhibition assays, apoptosis profiling, and structure-guided analogue design to improve potency and further characterize its anticancer mechanism. Furthermore, to fully establish the therapeutic potential of this scaffold, our future investigations will be directed towards screening across multiple cancer cell lines to guide further lead-optimization campaign.

4. Experimental section

4.1. General information

All reagents and solvents were purchased from commercial suppliers (Sigma-Aldrich, Merck, and TCI Chemicals) and used without further purification unless otherwise stated. Reactions were monitored by thin-layer chromatography (TLC) on silica gel 60 F254 aluminium plates (Merck) under UV light (254 nm and 366 nm). Column chromatography was performed using silica gel 60 (70–230 mesh, Merck). Melting points were recorded using an open capillary apparatus (Rieckhof, Germany) and are uncorrected. 1H and 13C NMR spectra were recorded on a Bruker 300 MHz spectrometer (300 MHz for 1H, 75 MHz for 13C) & Bruker 400 MHz spectrometer (400 MHz for 1H, 100 MHz for 13C) in CDCl3 & DMSO-d6 with TMS as internal standard. Chemical shifts are reported in parts per million (δ, ppm) and coupling constants (J) in hertz (Hz). Multiplicity abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. IR spectra were recorded using an FTIR spectrophotometer (PerkinElmer, USA) in KBr pellets. High-resolution mass spectra (HRMS) were obtained on a Agilent LC/Q-TOF instrument.

4.2. Synthesis of morpholino pyrimidine intermediate 6

The key intermediate 6 was synthesized according to the procedure outlined in Scheme 2. 2-(Bis(methylthio)methylene) malononitrile 1 (1 equiv.) was dissolved in acetonitrile. To this solution, compound 2 (1.1 equiv.) was added in the presence of triethylamine (1.2 equiv.). The reaction mixture was stirred at 80 °C for overnight, resulting in the formation of 4-amino-2-(benzylthio)-6-(methylthio) pyrimidine-5-carbonitrile 3. Reaction mass was filtered and white solid obtained was washed with cold water 3 times to remove excess base. The solid was dried, and an 85% yield was observed.

The solid compound 3 was dissolved in dry dichloromethane (DCM) and cooled to 0 °C. m-Chloroperbenzoic acid (m-CPBA) (5 equiv.) was added portion wise under inert atmosphere, and the reaction was allowed to stir to room temperature for 3 h. Progress of reaction was monitored by TLC, after completion of reaction, DCM was evaporated and crude was extracted with EtOAc. Organic layer was washed with water, dried over Na2SO4 and concentrated. An off-white solid, 4-amino-2-(benzylsulfonyl)-6-(methylthio) pyrimidine-5-carbonitrile 4 was obtained in 82% yield. The resulting compound 4 was treated with morpholine (1.2 equiv.) in 1,4-dioxane, reaction mass was refluxed at 80 °C for 2 h and after completion of reaction, reaction mass was cooled to room temperature. 1,4-Dioxane was evaporated and crude material was purified by column chromatography, on silica gel (100 : 200 mesh), using 25–30% EtOAc: hexane as eluent. Desired compound 5 was obtained as off-white solid in 75% yield. Compound 5 was again oxidized under similar conditions as used for the synthesis of intermediate 4 to obtain 6 as an off-white solid in 77% yield.

4.3. General procedure for synthesis of target compounds 8(a–u)

To a solution of intermediate 6 (1.0 equiv.) in anhydrous DMF, the appropriate p-hydroxy benzamide 7(a–u), and potassium carbonate (2.5 equiv.) were added sequentially at room temperature under nitrogen atmosphere. Catalytic amount of 18-crown-6 was added and the reaction mixture was stirred at 65 oC for 4–6 hours, monitored by TLC. Upon completion, DMF was evaporated and crude was diluted with ethyl acetate (50 mL), washed with saturated water and brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (100 : 200 mesh) by using 2–5% MeOH : DCM to afford the solid target compounds 8(a–u). Spectroscopic data for representative and all compounds are provided in the SI.

4.3.1. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl)oxy)-N-methylbenzamide 8a

White solid, yield: 70%, m.p.: 210–212 °C; FT-IR (neat, ν cm−1): 3412, 3352 (NH2 str), 3216 (COInline graphic), 2203 (C–N), 1634 (CO̲NH), 1601(NH2 bend); 1H NMR (300 MHz, DMSO-d6) δ 8.50 (br s, 1H, NH), 7.89 (s, 2H), 7.42 (br s, 2H, NH2), 7.30 (s, 2H), 3.51 (br s, 8H), 2.78 (s, 3H, CH3); 13C NMR (75 MHz, DMSO-d6): δ 170.71, 166.33, 165.85 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.21, 154.37, 131.90, 128.85, 122.0, 115.79 (C̲N), 66.13, 64.05, 44.10, 26.74 (C̲H3); HRMS (ESI) (M + H)+ calcd for C17H18N6O3: 355.1513, found 355.1512.

4.3.2. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl)oxy)-N-propylbenzamide 8b

White solid, yield: 72%, m.p.: 170–172 °C; FT-IR (neat, υ cm−1): 3414, 3354 (NH2 str), 3233 (COInline graphic), 2215 (C–N), 1633 (Inline graphicNH), 1597 (NH2 bend); 1H NMR (300 MHz, DMSO-d6): δ 8.52 (br s, 1H, NH), 7.90 (d, J = 6 Hz, 2H), 7.43 (br s, 2H, NH2), 7.30 (d, J = 6 Hz, 2H), 3.52 (br s, 8H), 3.37 (t, 2H, CH̲2CH2CH3), 1.57–1.50 (m, 2H, CH2CH̲2CH3), 0.90 (t, 3H, CH3); 13C NMR (75 MHz, DMSO-d6): δ 170.55, 165.85, 165.78 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.23, 154.34, 132.08, 128.96, 121.91, 115.78 (C̲N), 66.14, 64.07, 44.12, 41.51(C̲H2CH2CH3), 22.85 (CH2C̲H2CH3), 11.98 (C̲H3); HRMS (ESI) (M + H)+ calcd for C19H22N6O3: 383.1826, found 383.1827.

4.3.3. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl)oxy)-N-isopropylbenzamide 8c

Off-white solid, yield: 71%, m.p.: 242–244 °C; FT-IR (neat, υ cm−1): 3393, 3306 (NH2 str), 3206 (COInline graphic), 2207 (C–N), 1635 (Inline graphicNH), 1599 (NH2 bend); 1H NMR (400 MHz, DMSO-d6): δ 8.26 (d, 1H, NH), 7.91 (d, J = 8 Hz, 2H), 7.40 (br s, 2H, NH2), 7.29 (d, J = 8 Hz, 2H), 4.12–4.07 (m, 1H, CH̲(CH3)2), 3.52 (br s, 8H), 1.17 (d, 6H, (CH3)2); 13C NMR (75 MHz, DMSO-d6): δ 170.55, 165.85, 164.94 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.23, 154.31, 132.15, 129.07, 121.83, 115.79 (C̲N), 66.14, 64.06, 44.11, 41.51 (C̲H(CH3)2), 22.80 (CH3); HRMS (ESI) (M + H)+ calcd for C19H22N6O3: 383.1826, found 383.1825.

4.3.4. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl)oxy)-N,N-dimethylbenzamide 8d

White solid, yield: 74%, m.p.: 172–174 °C; FT-IR (neat, υ cm−1): 3400, 3331 (NH2 str), 3224 (COInline graphic), 2202 (C–N), 1645 (Inline graphicNH), 1603 (NH2 bend); 1H NMR (300 MHz, DMSO-d6): δ 7.45 (d, J = 9 Hz, 4H), 7.26 (d, J = 9 Hz, 2H), 3.52 (br s, 8H), 2.98 (s, 3H, CH3), 2.92 (s, 3H, CH3); 13C NMR (75 MHz, DMSO-d6): δ 170.66, 169.99, 165.87 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.21, 152.86, 133.82, 128.77, 122.05, 115.79 (C̲N), 66.14, 64.03, 44.12, 35.31(CH3); HRMS (ESI) (M + H)+ calcd for C18H20N6O3: 369.1670, found 369.1676.

4.3.5. 4-(3-Amino-2-cyano-5-morpholinophenoxy)-N-butylbenzamide 8e

White solid, yield: 70%, m.p.: 126–128 °C; FT-IR (neat, υ cm−1): 3401, 3362 (NH2 str), 3160 (COInline graphic), 2210 (C–N), 1705 (Inline graphicNH), 1631 (NH2 bend); 1H NMR (300 MHz, DMSO-d6): δ 8.49 (t, 1H, NH), 7.89 (d, J = 9 Hz, 2H), 7.41 (br s, 2H, NH2), 7.29 (d, J = 9 Hz, 2H), 3.52 (br s, 8H), 3.26 (q, 2H, NHCH̲2), 1.51(quint, 2H, NHCH2CH̲2), 1.40–1.32 (m, 2H, CH2CH2CH̲2CH3), 0.93 (t, 3H, CH2CH̲3); 13C NMR (75 MHz, DMSO-d6): δ 170.55, 165.87, 165.72 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.25, 154.35, 132.10, 128.95, 121.88, 115.76 (C̲N), 66.15, 64.11, 44.13, 40.8 (NHC̲H2), 31.71(NHCH2C̲H2), 20.16 (CH2CH2C̲H2CH3), 14.20 (CH2C̲H3); HRMS (ESI) (M + H)+ calcd for C20H24N6O3: 397.1983, found 397.1980.

4.3.6. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl)oxy)-N-(tert-butyl) benzamide 8f

Off-white solid, yield: 70%, m.p.: 176–178 °C; IR (neat, υ cm−1): 3460, 3310 (NH2 str), 3216 (COInline graphic), 2204 (C–N), 1625(Inline graphicNH), 1605 (NH2 bend), 1H NMR (300 MHz, DMSO-d6): δ 7.89 (s, 1H, NH), 7.84 (d, J = 9 Hz, 2H), 7.42 (br s, 2H, NH2), 7.26 (d, J = 9 Hz, 2H), 3.64–3.52 (br s, 8H), 1.23 (s, 9H, (CH3)3); 13C NMR (75 MHz, DMSO-d6): δ 170.50, 166.13, 165.83 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.21, 154.11, 133.04, 129.18, 121.68, 115.86 (C̲N), 66.13, 63.96, 51.39 (C̲H(CH3)3), 44.09, 28.95 (CH(C̲H3)3); HRMS (ESI) (M + H)+ calcd for C20H24N6O3: 397.1983, found 397.1992.

4.3.7. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl)oxy)-N-cyclopropylbenzamide 8g

White solid, yield: 78%, m.p.: 150–152 °C; IR (neat, υ cm−1): 3410, 3321(NH2 str), 3228 (COInline graphic), 2217 (C–N), 1635(Inline graphicNH), 1599 (NH2 bend); 1H NMR (300 MHz, DMSO-d6): δ 8.48 (br s, 1H, NH), 7.87 (d, J = 9 Hz, 2H), 7.40 (br s, 2H, NH2), 7.28 (d, J = 9 Hz, 2H), 3.52 (br s, 8H), 2.85 (s, 1H, CH̲(CH2)2), 0.71–0.69 (br s, 2H, CH2), 0.59 (s, 2H, CH2); 13C NMR (75 MHz, DMSO-d6): δ 170.54, 167.14, 165.87 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.24, 154.43, 131.78, 128.99, 121.87, 115.74 (C̲N), 66.14, 64.12, 44.13, 23.54 (C̲H(CH2)2), 6.17 (CH(C̲H2)2); HRMS (ESI) (M + H)+ calcd for C19H20N6O3: 381.1670, found 381.1669.

4.3.8. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl)oxy)-N-cyclopentylbenzamide 8h

Off-white solid, yield: 72%, m. p.: 212–214 °C; IR (neat, υ cm−1): 3416, 3334 (NH2 str), 3272 (COInline graphic), 2212 (C–N), 1630 (Inline graphicNH), 1601 (NH2 bend); 1H NMR (400 MHz, DMSO-d6): δ 8.31 (d, 1H, NH), 7.90 (d, J = 8.8, 2H), 7.39 (br s, 2H, NH2), 7.28 (d, J = 8.8, 2H), 4.24–4.19 (m, 1H, CH̲(CH2)2), 3.51 (br s, 8H), 1.88–1.87 (m, 2H,CH2), 1.69–1.66 (m, 2H, CH2), 1.57–1.53 (m, 4H, CH2); 13C NMR (75 MHz, DMSO-d6): δ 170.56, 165.85, 165.50 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.24, 154.31, 132.12, 129.13, 121.81, 115.78 (C̲N), 66.15, 64.06, 51.45 (C̲H(CH2)2, 44.12, 32.56 (CHC̲H2), 24.10 (CHCH2C̲H2); HRMS (ESI) (M + H)+ calcd for C21H24N6O3: 409.1983, found 409.1997.

4.3.9. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl)oxy)-N-cyclohexylbenzamide 8i

Pale white solid, yield: 70%, m.p.: 260–262 °C; IR (neat, υ cm−1): 3413, 3316 (NH2 str), 3234 (COInline graphic), 2213 (C–N), 1635 (Inline graphicNH), 1596 (NH2 bend); 1H NMR (400 MHz, DMSO-d6): δ 8.24 (d, 1H, NH), 7.90 (d, J = 8 Hz, 2H), 7.40 (br s, 2H, NH2), 7.28 (d, J = 8 Hz, 2H), 3.76 (br s, 1H, CH̲(CH2)2), 3.52 (br s, 8H), 1.83–1.73 (m, 4H, CH2), 1.63–1.60 (m, 1H, CH2), 1.31 (t, 4H, CH2), 1.16–1.11 (m, 1H, CH2); 13C NMR (75 MHz, DMSO-d6): δ 170.55, 165.87, 164.95 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.27, 154.33, 132.21, 129.12, 121.78, 115.76 (C̲N), 66.15, 64.12, 48.89, 44.15, 32.89, 25.79, 25.43; HRMS (ESI) (M + H)+ calcd for C22H26N6O3: 423.2139, found 423.2133.

4.3.10. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl)oxy)-N-phenylbenzamide 8j

Off-white solid, yield: 70%, m.p.: 184–186 °C; IR (neat, υ cm−1): 3336, 3277 (NH2 str), 3233 (COInline graphic), 2220 (C–N), 1646 (Inline graphicNH), 1603 (NH2 bend); 1H NMR (300 MHz, DMSO-d6): δ 10.30 (s, 1H, NH), 8.04 (d, J = 9 Hz, 2H), 7.78 (d, J = 9 Hz, 2H), 7.40–7.34 (m, 6H), 7.12 (d, J = 6 Hz, 1H), 3.53 (br s, 8H); 13C NMR (75 MHz, DMSO-d6): δ 170.53, 165.87, 165.11(C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.24, 154.81, 139.55, 132.21, 129.59, 129.09, 124.19, 122.09, 120.89, 115.78 (C̲N), 66.16, 64.13, 44.14; HRMS (ESI) (M + H)+ calcd for C20H20N6O3: 417.1670, found 417.1668.

4.3.11. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl)oxy)-N-(4-bromophenyl) benzamide 8k

Off-white solid, yield: 74%, m.p.: 246–248 °C; IR (neat, υ cm−1): 3414, 3334 (NH2 str), 3231 (CONH), 2216 (C–N), 1650 (Inline graphicNH), 1596 (NH2 bend); 1H NMR (300 MHz, DMSO-d6): δ 10.42(s, 1H, NH), 8.03 (d, J = 9 Hz, 2H), 7.77 (d, J = 9 Hz, 2H), 7.54 (d, J = 9 Hz, 2H), 7.45 (br s, 2H, NH2), 7.39 (d, J = 9 Hz, 2H), 3.53 (br s, 8H); 13C NMR (75 MHz, DMSO-d6): 170.51, 165.86, 165.21 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.23, 154.94, 138.96, 131.92, 129.64, 122.73, 122.14, 115.87, 115.77 (C̲N), 66.15, 64.13, 44.14; HRMS (ESI) (M + H)+ calcd for C22H19BrN6O3: 495.0775, found 495.0772.

4.3.12. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl) oxy)-N-(3-chloro-4-fluorophenyl) benzamide 8l

White solid, yield: 74%, m.p.: 130–132 °C; IR (neat, υ cm−1): 3450, 3336 (NH2 str), 3233 (COInline graphic), 2217 (C–N), 1645 (Inline graphicNH), 1607 (NH2 bend); 1H NMR (300 MHz, DMSO-d6): δ 10.48 (s, 1H, NH), 8.09 (d, J = 6 Hz, 1H), 8.03(d, J = 9 Hz, 2H), 7.73 (d, J = 9 Hz, 1H), 7.46–7.40 (m, 5H), 3.53 (br s, 8H); 13C NMR (75 MHz, DMSO-d6): δ 170.50, 165.86, 165.23 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.23, 155.24, 152.22, 136.85, 131.65, 129.64, 122.20, 121.17, 121.07, 119.46, 117.30, 115.76 (C̲N), 66.15, 64.14, 44.14; HRMS(ESI) (M + Na)+ calcd for C22H18ClFN6O3: 491.1011, found 491.1003.

4.3.13. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl) oxy)-N-(4-fluorophenyl) benzamide 8m

Off-white solid, yield: 78%, m.p.: 218–220 °C; IR (neat, υ cm−1): 3344, 3337 (NH2 str), 3235 (COInline graphic), 2219 (C–N), 1665 (Inline graphicNH), 1638 (NH2 bend), 1H NMR (300 MHz, DMSO-d6): δ 10.36 (s, 1H, NH), 8.03 (d, J = 9 Hz, 2H), 7.80 (t, J = 9 Hz, 2H), 7.45 (br s, 2H, NH2), 7.39 (d, J = 9 Hz, 2H), 7.21 (t, J = 9 Hz, 2H), 3.53 (br s, 8H); 13C NMR (75 MHz, DMSO-d6): δ 170.52, 165.87, 165.04 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.31, 157.20, 154.85, 135.88, 132.03, 129.56, 122.74, 122.11, 115.82, 115.64 (C̲N), 66.15, 64.14, 44.14; HRMS (ESI) (M + H)+ calcd for C22H19FN6O3: 435.1575, found 435.1609.

4.3.14. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl) oxy)-N-(4-(trifluoromethyl)phenyl) benzamide 8n

Off-white solid, yield: 68%, m.p.: 248–250 °C; IR (neat, υ cm−1): 3413, 3335 (NH2 str), 3231 (COInline graphic), 2216 (C–N), 1651 (Inline graphicNH), 1597 (NH2 bend); 1H NMR (300 MHz, DMSO-d6): δ 10.64 (s, 1H, NH), 8.05 (t, J = 9 Hz, 4H), 7.74 (d, J = 9 Hz, 2H), 7.46 (br s, 2H, NH2), 7.41 (d, J = 9 Hz, 2H), 3.53 (br s, 8H); 13C NMR (75 MHz, DMSO-d6): δ 170.50, 165.86, 165.58 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.23, 155.11, 143.25, 131.71, 129.80, 126.43, 126.38, 123.87, 122.19, 120.60 115.76 (C̲N), 66.15, 64.15, 44.15; HRMS (ESI) (M + Na)+ calcd for C23H19F3N6O3: 507.1368, found 507.1360.

4.3.15. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl)oxy)-N-(4-chlorophenyl) benzamide 8o

Light yellow solid, yield: 78%, m.p.: 230–232 °C; IR (neat, υ cm−1): 3411, 3333 (NH2 str), 3230 (COInline graphic), 2215 (C–N), 1648 (Inline graphicNH), 1597 (NH2 bend); 1H NMR (300 MHz, DMSO-d6): δ 10.43 (s, 1H, NH), 8.03 (d, J = 9 Hz, 2H), 7.82 (d, J = 9 Hz, 2H), 7.41 (br s, 2H, NH2), 7.39 (d, J = 9 Hz, 4H), 3.53 (br s, 8H); 13C NMR (75 MHz, DMSO-d6): δ 170.51, 165.86, 165.19 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.23, 154.94, 138.55, 131.92, 129.01, 127.77, 122.36, 122.13, 115.76 (C̲N), 66.16, 64.14, 44.15; HRMS (ESI) (M + Na)+ calcd for C22H19ClN6O3: 473.1105, found 473.1097.

4.3.16. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl) oxy)-N-(4-methoxyphenyl) benzamide 8p

Off-white solid, yield: 65%, m.p.: 198–200 °C; IR (neat, υ cm−1): 3430, 3336 (NH2 str), 3244 (COInline graphic), 2217 (C–N), 1646 (Inline graphicNH), 1593 (NH2 bend); 1H NMR (400 MHz, DMSO-d6, δ ppm): δ 10.19 (s, 1H, NH), 8.02 (d, J = 6 Hz, 2H), 7.67 (d, J = 9 Hz, 2H), 7.44 (s, 2H, NH2), 7.36 (d, J = 9 Hz, 2H), 6.93 (d, J = 9 Hz, 2H), 3.75 (s, 3H, OCH3), 3.52–3.43 (br s, 8H); 13C NMR (75 MHz, DMSO-d6): δ 170.55, 165.86, 164.65 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.24, 156.03, 154.68, 132.59, 132.29, 129.45, 122.49, 122.06, 115.78 (C̲N), 114.20, 66.16, 64.11, 55.63, 44.13; HRMS (ESI) (M + H)+ calcd for C23H22N6O4: 447.1775, found 447.1771.

4.3.17. 4-((6-Amino-5-cyano-2-morpholinopyrimidin-4-yl) oxy)-N-benzylbenzamide 8q

Pale-white solid, yield: 67%, m.p.: 206–208 °C; IR (neat, υ cm−1): 3467, 3333 (NH2 str), 3226 (COInline graphic), 2207 (C–N), 1623 (Inline graphicNH), 1599 (NH2 bend); 1H NMR (300 MHz, DMSO-d6): δ 9.11 (t, 1H, NH), 7.95 (d, J = 9 Hz, 2H), 7.43 (br s, 2H, NH2), 7.34–7.31 (m, 6H), 7.25 (t, J = 9 Hz, 1H), 4.48 (d, 2H, NHCH̲2), 3.52 (br s, 8H); 13C NMR (75 MHz, DMSO-d6): δ 170.52, 165.91, 165.85 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.22, 154.54, 140.07, 131.70, 129.10, 128.77, 127.79, 127.26, 122.01, 115.79 (C̲N), 66.14, 64.09, 44.13, 43.14; HRMS (ESI) (M + H)+ calcd for C23H22N6O3: 431.1826, found 431.1823.

4.3.18. 4-Amino-2-morpholino-6-(4-(pyrrolidine-1-carbonyl) phenoxy) pyrimidine-5-carbonitrile 8r

Off-white solid, yield: 68%, m.p.: 192–194 °C; IR (neat, υ cm−1): 3425, 3306 (NH2 str), 2196 (C–N), 1645 (Inline graphicNH), 1607 (NH2 bend); 1H NMR (400 MHz, DMSO-d6, δ ppm): δ 7.56 (d, J = 6.3 Hz, 2H), 7.39 (br s, 2H, NH2), 7.25 (d, J = 6.3 Hz, 2H), 3.51 (br s, 8H), 3.44 (t, 2H, NCH2), 3.38 (t, 2H, NCH̲2), 1.88–1.80 (m, 4H, CH2CH̲2CH2); 13C NMR (75 MHz, DMSO-d6): 170.63, 167.95, 165.88 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.23, 153.17, 134.58, 128.90, 121.92, 115.77 (C̲N), 66.15, 64.09, 46.49, 44.14, 26.47; HRMS (ESI) (M + H)+ calcd for C20H22N6O3: 395.1826, found 395.1823.

4.3.19. 4-Amino-2-morpholino-6-(4-(piperidine-1-carbonyl) phenoxy)pyrimidine-5-carbonitrile 8s

Off-white solid, yield: 63%, m.p.: 178–180 °C; IR (neat, υ cm−1): 3379, 3328 (NH2 str), 2206 (C–N), 1635 (Inline graphicNH), 1604 (NH2 bend); 1H NMR (400 MHz, DMSO-d6): δ 7.41 (d, J = 8 Hz, 4H), 7.26 (d, J = 8 Hz, 2H), 3.52–3.32 (bs, 12H), 1.62–1.50 (m, 6H); 13C NMR (75 MHz, DMSO-d6): δ 170.69, 168.74, 165.88 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.22, 152.83, 133.91, 128.40, 122.20, 115.76 (C̲N), 66.14, 64.07, 44.13, 24.51; HRMS (ESI) (M + H)+ calcd for C21H24N6O3: 409.1983, found 409.1979.

4.3.20. 4-Amino-6-(4-(4-methylpiperazine-1-carbonyl)phenoxy)-2-morpholinopyrimidine-5-carbonitrile 8t

Off-white solid, yield: 63%, m.p.: 138–140 °C; IR (neat, υ cm−1): 3467, 3333 (NH2 str), 3226 (COInline graphic), 2207 (C–N), 1626 (Inline graphicNH), 1600 (NH2 bend); 1H NMR (300 MHz, CDCl3): δ 7.46 (d, J = 6 Hz, 2H), 7.22 (d, J = 6 Hz, 2H), 5.35 (s, 2H, NH2), 3.75–3.48 (m, 12H), 2.49–2.35 (m, 7H); 13C NMR (75 MHz, DMSO-d6): δ 170.63, 168.82, 165.86 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.21, 153.00, 133.29, 128.73, 122.20, 115.76 (C̲N), 66.14, 64.06, 54.50, 46.05, 44.12; HRMS (ESI) (M + H)+ calcd for C21H25N7O3: 424.2092, found 424.2083.

4.3.21. 4-Amino-6-(4-(morpholine-4-carbonyl)phenoxy)-2-morpholinopyrimidine-5-carbonitrile 8u

Off-white solid, yield: 62%, m. p.: 194–196 °C; IR (neat, υ cm−1): 3409, 3318 (NH2 str), 3222 (COInline graphic), 2199 (C–N), 1633 (Inline graphicNH), 1599 (NH2 bend); 1H NMR (300 MHz, DMSO-d6) 7.47 (d, J = 9 Hz, 2H), 7.43 (br s, 2H, NH2), 7.28 (d, J = 9 Hz, 2H), 3.60 (br s, 8H), 3.52 (br s, 8H); 13C NMR (75 MHz, DMSO-d6): δ 170.61, 168.94, 165.87 (C Created by potrace 1.16, written by Peter Selinger 2001-2019 O), 160.22, 153.11, 132.91, 128.92, 122.20, 115.76 (C̲N), 66.50, 66.14, 64.09, 44.13; HRMS (ESI) (M + H)+ calcd for C20H22N6O4; 411.1775, found 411.1774.

4.4. Biological evaluation

4.4.1. MTT and Trypan Blue dye exclusion assay

MTT and Trypan Blue dye exclusion assays were performed as previously described. Briefly, HepG2 and human normal kidney cells (HEK293) were treated with different concentrations of the library of small molecules (10, 25, and 50 µM) and incubated for 72 hours; DMSO (0.1% v/v) was used as the negative control and cisplatin as the positive control. After incubation, cells were subjected to MTT and Trypan Blue dye assays. For the MTT assay, the plates were read spectrophotometrically at 570 nm using a Tecan Microplate Reader (Tecan Instruments, Switzerland). Trypan Blue-treated cells were counted using the Thermo Fisher Countess III FL Automated Cell Counter for calculating the percentage of live and dead cells. Data were analysed using Microsoft Excel to determine IC50 values. All experiments were performed in triplicate.

4.4.2. Haemolytic assay

To evaluate the cytotoxicity of the newly synthesized compounds on human erythrocytes, fresh blood was drawn from healthy adult volunteers with informed consent following protocol approval by the Adichunchanagiri Institute of Medical Science's ethical committee bearing registration number EC/NEW/INST/2023/KA/0382 and transferred into EDTA-containing tubes following protocol approval by the phosphate-buffered saline (PBS) and Triton X-100 were used as negative and positive controls, respectively. A 1% diluted RBC suspension was prepared and aliquoted to test samples containing different concentrations of each compound, followed by incubation at 37 °C for 24 hours. The samples were centrifuged at 1500 rpm for 5 minutes, and the absorbance of the supernatant was measured at 545 nm using a Shimadzu UV-1800 spectrophotometer. Percentage haemolysis was calculated relative to the Triton X-100 positive control.

4.5. Computational methods

DFT calculations: geometry optimization and electronic property calculations for all twenty-one compounds were performed at the B3LYP/6-311G(d,p) level of theory using Gaussian 16.23,24 All structures were confirmed as true energy minima by the absence of imaginary frequencies in frequency calculations. Frontier molecular orbital energies (EHOMO and ELUMO), energy gaps, and global chemical reactivity descriptors (ionization energy I, electron affinity A, chemical hardness η, chemical potential µ, electrophilicity index ω, and electronegativity χ) were computed according to Koopmans' theorem and established formulae: η = (I − A)/2; µ = −(I + A)/2; ω = µ2/2η; χ = (I + A)/2.25–27

Molecular docking: protein crystal structures of PI3Kγ (4L23), mTOR kinase domain (4DRH), Akt1 (4JT6), and PI3Kδ (6BCX) target proteins (.pdb format) were downloaded from RCSB (Research Collaboratory for Structural Bioinformatics) protein data bank (https://www.rcsb.org). The graphical user interface of Autodock Tools-1.5.7 (ref. 28) was used to prepare the proteins through the removal of water, defining and editing of binding sites, the addition of polar hydrogens as well as required charges. The geometries of all the ligands were optimized to minimum energy at B3LYP/6-311 G level of theory as implemented in Gaussian 16. The protein–ligand interactions were analyzed using the Discovery Studio 2021 Client29 to give the molecular binding mode and 2-D ligand–protein interaction. The docking conformation with the lowest binding energy was selected to study the mode of binding.

ADMET and drug-likeness prediction: drug-likeness and pharmacokinetic properties were predicted using the SwissADME web tool30 and ADMET Lab 3.0.31 Drug-likeness was evaluated according to Lipinski's Rule of Five. The Boiled Egg model was used to visualize predicted gastrointestinal absorption and BBB permeability. Bioavailability radar plots were generated using SwissADME.

Molecular dynamics simulations: MD simulation studies were carried out to understand the conformational and structural changes that occur during the formation of protein–ligand complexes. These were performed through YASARA software,32,33 with AMBER14 force field.34 The protein–ligand complex was placed in a water box that is 10 Å bigger than each side of the protein. Hydrogen atoms were added to the protein structure at appropriate ionizable groups that are identified according to the computed pKa in relation to the pH simulation. Thus, a hydrogen atom will be added, if the computed pKa is higher than the pH. Following the Ewald method,35,36 the pKa is computed to each residue. Subsequently, the structure was then minimized using the steepest-descent method followed by simulated annealing. The simulation was performed at pH 7.0 in a 0.9% NaCl solution at 300 K temperature for 100 ns. A cut-off of 7.86 Å was used for van-der-Waals forces and the Particle Mesh Ewald algorithm37 was used for electrostatic forces. A multiple time step of 2.5 and 5 fs was used for intra-molecular and inter-molecular forces, respectively.

Conflicts of interest

The authors declare no conflicts of interest, financial or otherwise.

Supplementary Material

RA-OLF-D6RA07731E-s001
RA-OLF-D6RA07731E-s002

Acknowledgments

NS acknowledge funding from SERB (TAR/2021/000189). TY acknowledges UGC for JRF. The authors sincerely thank the management of SGT University, Gurugram, Haryana, and THSTI, Faridabad, Haryana for providing the necessary facilities to conduct and submit this research. We also acknowledge Dr Dinesh Mahajan for his mentorship and THSTI for providing the NMR facility. The authors sincerely thank Prof. Dr Stella Stopkowicz, University of Saarland, Saarbrucken, Germany, for providing access to her computational facility (Gaussian 16 software), which is instrumental in carrying out the DFT studies for this article.

Data availability

The data supporting this article have been included as part of the supplementary information (SI). Supplementary information is available. See DOI: https://doi.org/10.1039/d6ra07731e.

References

  1. Taylor R. D. MacCoss M. Lawson A. D. G. J. Med. Chem. 2014;57:5845–5859. doi: 10.1021/jm4017625. [DOI] [PubMed] [Google Scholar]
  2. Lagoja I. M. Chem. Biodiversity. 2005;2:1–50. doi: 10.1002/cbdv.200490173. [DOI] [PubMed] [Google Scholar]
  3. Verma S. Rani A. Sinha R. Narasimhan B. Future Med. Chem. 2021;13:1851–1876. [Google Scholar]
  4. Capdeville R. Buchdunger E. Zimmermann J. Matter A. Nat. Rev. Drug Discovery. 2002;1:493–502. doi: 10.1038/nrd839. [DOI] [PubMed] [Google Scholar]
  5. Iorkula T. H. Osayawe O. J. Odogwu D. A. Ganiyu L. O. Faderin E. Awoyemi R. F. Akodu B. O. Ifijen I. H. Aworinde O. R. Agyemang P. Onyinyechi O. L. RSC Adv. 2025;5:3756–3828. doi: 10.1039/D4RA07556K. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Holohan C. Van Schaeybroeck S. Longley D. B. Johnston P. G. Nat. Rev. Cancer. 2013;13:714–726. doi: 10.1038/nrc3599. [DOI] [PubMed] [Google Scholar]
  7. Kourounakis A. P. Tzara A. Xanthopoulos D. Doxakis K. Med. Res. Rev. 2020;40:709–752. doi: 10.1002/med.21634. [DOI] [PubMed] [Google Scholar]
  8. Arshad F. Khan M. F. Akhtar W. Alam M. M. Nainwal L. M. Kaushik S. K. Akhter M. Parvez S. Hasan S. M. Shaquiquzzaman M. Eur. J. Med. Chem. 2019;167:324–356. doi: 10.1016/j.ejmech.2019.02.015. [DOI] [PubMed] [Google Scholar]
  9. Vitaku E. Smith D. T. Njardarson J. T. J. Med. Chem. 2014;57:10257–10274. doi: 10.1021/jm501100b. [DOI] [PubMed] [Google Scholar]
  10. Kumari A. Singh R. K. Bioorg. Chem. 2020;96:103578. doi: 10.1016/j.bioorg.2020.103578. [DOI] [PubMed] [Google Scholar]
  11. Vanhaesebroeck B. Guillermet-Guibert J. Graupera M. Bilanges B. Nat. Rev. Mol. Cell Biol. 2010;11:329–341. doi: 10.1038/nrm2882. [DOI] [PubMed] [Google Scholar]
  12. Dwivedi A. R. Kumar V. Prashar V. Verma A. Kumar N. Prakash J. Kumar V. RSC Med. Chem. 2022;12:599–609. doi: 10.1039/D2MD00023G. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Metwaly A. M. Elgammal W. E. Eissa I. H. Mahdy H. A. Taghour M. S. Alsfouk A. A. Amin F. G. Husein D. Z. Elkaeed E. B. Elkady H. RSC Adv. 2026;16:46282–46300. doi: 10.1039/D6RA03459D. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Santoso P. Danova A. Aonbangkhen C. Chatwichien J. Natalia D. Hermawati E. Chavasiri W. Alni A. J. Mol. Struct. 2025;1348:143593. doi: 10.1016/j.molstruc.2025.143593. [DOI] [Google Scholar]
  15. Anwer K. E. El-Dydamony N. Saleh A. Altwaijry N. Husseiny E. M. Drug Dev. Res. 2025;86:e70139. doi: 10.1002/ddr.70139. [DOI] [PubMed] [Google Scholar]
  16. Helwa A. A. El-Dydamony N. M. Radwan R. A. Abdelraouf S. M. Abdelnaby R. M. Bioorg. Chem. 2020;102:104051. doi: 10.1016/j.bioorg.2020.104051. [DOI] [PubMed] [Google Scholar]
  17. Rady G. S. El Deeb M. A. Sarg M. T. M. Taher A. T. Helwa A. A. RSC Med. Chem. 2024;15(2):733–752. doi: 10.1039/D3MD00693J. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Bissantz C. Kuhn B. Stahl M. J. Med. Chem. 2010;53:5061–5084. doi: 10.1021/jm100112j. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fleming F. F. Yao L. Ravikumar P. C. Funk L. Shook B. C. J. Med. Chem. 2010;53:7902–7917. doi: 10.1021/jm100762r. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ahmed N. M. Mohamed M. S. Awad S. M. Abd El-tawab N. A. Gaballah M. S. Said A. M. J. Enzyme Inhib. Med. Chem. 2024;39:2304625. doi: 10.1080/14756366.2024.2304625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Reda N. Elshewy A. El-Askary H. I. Mohamed K. O. Helwa A. A. RSC Adv. 2023;13:32296–32320. doi: 10.1039/D3RA06088H. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Bo Y.-X. Xiang R. Xu Y. Hao S.-Y. Wang X.-R. Chen S.-W. Bioorg. Med. Chem. 2020;28:115351. doi: 10.1016/j.bmc.2020.115351. [DOI] [PubMed] [Google Scholar]
  23. Becke A. D. J. Chem. Phys. 1993;98:5648–5652. doi: 10.1063/1.464913. [DOI] [Google Scholar]
  24. Frisch M. J., Trucks G. W., Schlegel H. B. and et al., Gaussian 16, Revision B.01, Gaussian, Inc., Wallingford, 2016 [Google Scholar]
  25. Parr R. G. Pearson R. G. J. Am. Chem. Soc. 1983;105:7512–7516. doi: 10.1021/ja00364a005. [DOI] [Google Scholar]
  26. Mulliken R. S. J. Chem. Phys. 1934;2:782–793. doi: 10.1063/1.1749394. [DOI] [Google Scholar]
  27. Yang W. Parr R. G. Proc. Natl. Acad. Sci. U. S. A. 1985;82:6723–6726. doi: 10.1073/pnas.82.20.6723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Pal S. Chaudary M. Kala K. Int. J. Pharm. Sci. 2025;3:3005–3019. [Google Scholar]
  29. Baroroh U. Muscifa S. Z. Destiarani W. Rohmatulloh G. F. Yusuf M. Indones. J. Comput. Bio. 2023;2:22–30. [Google Scholar]
  30. Daina A. Michielin O. Zoete V. Sci. Rep. 2017;7:42717. doi: 10.1038/srep42717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Fu L. Shi S. Yi J. Wang N. He Y. Wu Z. Peng J. Deng Y. Wang W. Wu C. Lyu A. Zeng X. Zhao W. Hou T. Cao D. Nucleic Acids Res. 2024;52:W422–W431. doi: 10.1093/nar/gkae236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Krieger E. Joo K. Lee J. Lee J. Raman S. Thompson J. Tyka M. Baker D. Karplus K. Proteins. 2009;77:114–122. doi: 10.1002/prot.22570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Krieger E. Vriend G. J. Comput. Chem. 2025;36:996–1007. doi: 10.1002/jcc.23899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Cornell W. D. Cieplak P. Bayly C. I. Gould I. R. Merz K. M. Ferguson D. M. Spellmeyer D. C. Fox T. Caldwell J. W. Kollman P. A. J. Am. Chem. Soc. 1995;117:5179–5197. doi: 10.1021/ja00124a002. [DOI] [Google Scholar]
  35. Eisenberg D. Luthy R. Bowie J. U. Enzymol. 1997;277:396–404. doi: 10.1016/s0076-6879(97)77022-8. [DOI] [PubMed] [Google Scholar]
  36. Cheatham T. I. Miller J. L. Fox T. Darden T. A. Kollman P. A. J. Am. Chem. Soc. 1995;117:4193–4194. doi: 10.1021/ja00119a045. [DOI] [Google Scholar]
  37. Essmann U. Perera L. Berkowitz M. L. Darden T. Lee H. Pedersen L. G. J. Chem. Phys. 1995;103:8577–8593. doi: 10.1063/1.470117. [DOI] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

RA-OLF-D6RA07731E-s001
RA-OLF-D6RA07731E-s002

Data Availability Statement

The data supporting this article have been included as part of the supplementary information (SI). Supplementary information is available. See DOI: https://doi.org/10.1039/d6ra07731e.


Articles from RSC Advances are provided here courtesy of Royal Society of Chemistry

RESOURCES